Epichem Awarded Major US Drug Discovery Contract Extension
Filed with ASX · · 1 page · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- MPL successfully reformulated for canine clinical trials
- Chief Executive Officer resigns
- Appendix 4C & Company Update
- PharmAust enters option to license agreement with Elanco
- Appendix 4D and Half Yearly Report & Accounts
Later from Neurizon Therapeutics
- Epichem gains prestigious international ISO accreditation
- Appendix 4C & Company Update - June 18
- Reformulation of MPL into tablet form for upcoming trials
- Olivia Newton-John Cancer Reseach Institute collaboration
- PharmAust Progresses Monepantel Tablet Program for Cancer
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics